Head-to-head evidence
Budesonide (Entocort EC) vs budesonide (Ortikos)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: Glucocorticoid receptor · full Crohn's Disease pipeline
Budesonide (Entocort EC)
Marketed by Padagis
NCT01444092 · Phase 3 · completed
This was a single-arm, open-label study without randomization, blinding, or a comparator, so its findings cannot reliably distinguish Entocort’s effects from the natural course of disease or other factors. The primary safety endpoint was descriptive rather than a comparative efficacy test, with 79 of 108 treated participants reporting at least one adverse event.
budesonide (Ortikos)
Marketed by Sun Pharmaceutical Industries
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Entocort EC)'s landscape · budesonide (Ortikos)'s landscape